¼¼°èÀÇ ¼ºÀåÈ£¸£¸ó °áÇÌÁõ ½ÃÀå
Growth Hormone Deficiency
»óǰÄÚµå : 1731087
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 475 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼ºÀåÈ£¸£¸ó °áÇÌÁõ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 52¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 44¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼ºÀåÈ£¸£¸ó °áÇÌÁõ ¼¼°è ½ÃÀåÀº 2024-2030³â CAGR 3.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 52¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Ä¡·áÁ¦´Â CAGR 2.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 19¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯ÀüÀÚ ÀçÁ¶ÇÕ Àΰ£¼ºÀåÈ£¸£¸ó Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯, Áß±¹Àº CAGR 5.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¼ºÀåÈ£¸£¸ó °áÇÌÁõ½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.7%·Î¼­ 2030³â±îÁö 10¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.3%¿Í 2.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.7%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¼ºÀåÈ£¸£¸ó °áÇÌÁõ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

¼ºÀåÈ£¸£¸ó °áÇÌÀÌ ¼Ò¾Æ°ú¿Í ¼ºÀÎ ÀÇÇп¡¼­ ÁÖ¸ñ¹Þ°Ô µÈ ÀÌÀ¯´Â ¹«¾ùÀϱî?

µå¹°Áö¸¸ Áß¿äÇÑ ³»ºÐºñ ÁúȯÀÎ ¼ºÀåÈ£¸£¸ó °áÇÌÁõ(GHD)Àº ¼Ò¾Æ ¹× ¼ºÀÎ Áý´Ü¿¡¼­ Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Ä¡·á¹ýÀÌ È®´ëµÊ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ´ë»ç ºÒ±ÕÇüÀ» ÃÊ·¡ÇÕ´Ï´Ù. °ú°Å¿¡´Â ¼Ò¾Æ ÁúȯÀ¸·Î ¿©°ÜÁ³Áö¸¸, ³úÇϼöü Á¾¾ç, ¿Ü»ó ¶Ç´Â ³ëÈ­¿Í °ü·ÃµÈ ¼ºÀÎ ¹ßº´ GHD´Â ÇöÀç ´õ ÀÚÁÖ Áø´ÜµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ´õ ³ÐÀº ȯÀÚ±º°ú Áö¼ÓÀûÀÎ Ä¡·á ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀûÀ¸·Î GHDÀÇ ¹ß»ý·üÀº ºñ±³Àû ³·Àº ÆíÀÌÁö¸¸, ÀÌ ÁúȯÀÇ º¹ÀâÇÑ Áõ»ó°ú Àå±âÀûÀÎ ÇÕº´ÁõÀ¸·Î ÀÎÇØ Á¶±â ¹ß°ß°ú Á¶±â °³ÀÔ¿¡ ´ëÇÑ ÀÓ»óÀû ÃÊÁ¡ÀÌ ÁýÁߵǰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ¿¡¼­ GHD¸¦ Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡Çϸé Àú½ÅÀå, »çÃá±â Áö¿¬, »À ¹ß´Þ Àå¾Ö°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ºÀÎÀÇ °æ¿ì ±ÙÀ°·® °¨¼Ò, ÇǷΰ¨, Áö¹æ ÃàÀû Áõ°¡, »îÀÇ Áú ÀúÇÏ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ»óÀº È£¸£¸ó ¼öÄ¡ °Ë»ç ¹× ¿µ»ó Áø´ÜÀÇ ¹ßÀü°ú ÇÔ²² Áö¿ª Àüü¿¡¼­ ½Äº°·üÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¢±Ù¼º Çâ»ó°ú ³»ºÐºñÇÐȸÀÇ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ Áø´ÜÀÇ ¹ßÀÚÃ븦 ´õ¿í ³ÐÇô°¡°í ÀÖ½À´Ï´Ù.

ȯÀÚÀÇ ´ÏÁî¿Í ±â¼ú Çõ½Å¿¡ µû¶ó Ä¡·á ¹æ¹ýÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

GHDÀÇ Ç¥ÁØ Ä¡·á´Â À¯ÀüÀÚ ÀçÁ¶ÇÕ Àΰ£¼ºÀåÈ£¸£¸ó(rhGH)À» ¸ÅÀÏ ÇÇÇÏ ÁÖ»çÇÏ´Â °ÍÀ¸·Î, È£¸£¸ó ¼öÄ¡ ȸº¹°ú ÀÓ»ó °á°ú °³¼±¿¡ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ±×·¯³ª ÀæÀº ÁÖ»çÀÇ ºÎ´ã°ú º¹¾à ¼øÀÀµµ ¹®Á¦(ƯÈ÷ ¼Ò¾Æ)·Î ÀÎÇØ ¾à¹°ÀÇ Á¦Çü°ú Àü´Þ ¹æ½Ä¿¡ Å« Çõ½ÅÀ» °¡Á®¿Ô½À´Ï´Ù. ¼Ò¸¶ÆÄ½Ãź, ·Î³ªÆä±×¼Ò¸¶Å䯮·ÎÇɰú °°Àº Áö¼ÓÇü ¼ºÀåÈ£¸£¸ó À¯»çüµéÀÌ ÇöÀç ½ÃÀå¿¡ Ãâ½ÃµÇ¾î ÁÖ 1ȸ ¶Ç´Â ±× ÀÌÇÏ·Î Åõ¿©ÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ȯÀÚÀÇ ÆíÀǼº°ú º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À Á¦¾à»çµéÀº ÁÖ»ç¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â Àü´Þ ±â¼ú, ¼­¹æÇü ¸¶ÀÌÅ©·Î½ºÇÇ¾î ½Ã½ºÅÛ, ÀÚµ¿ ÁÖ»ç±â ÆæÀ» ÅëÇØ Åõ¿©¸¦ °£¼ÒÈ­Çϰí Áֻ翡 µû¸¥ ºÒÆíÇÔÀ» ÁÙÀÌ´Â µ¥¿¡µµ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¹ÙÀÌ¿À¸¶Ä¿¿Í À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµÀ» Ȱ¿ëÇÑ °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýµµ °ËÅäµÇ°í ÀÖÀ¸¸ç, À̸¦ ÅëÇØ Åõ¿© Àü·«À» Á¶Á¤Çϰí Ä¡·á ¹ÝÀÀÀ» º¸´Ù Á¤È®ÇÏ°Ô ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µ, ȯÀÚ ¾Ë¸², ¸ð¹ÙÀÏ ±â¹Ý ¼øÀÀµµ ÃßÀûÀ» °¡´ÉÇÏ°Ô ÇÏ´Â µðÁöÅÐ Çコ Ç÷§ÆûÀº ƯÈ÷ ¿ø°Ý ÀÇ·á ÀÎÇÁ¶ó°¡ ¼º¼÷ÇÑ ¼±Áø Áö¿ª¿¡¼­ GHD °ü¸® ÇÁ·ÎÅäÄݰú ÅëÇյǰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀå¿¡¼­ ¼ºÀåÀÇ Ã˸ÅÁ¦·Î ¶°¿À¸£°í ÀÖ´Â ºÎ¹®¿Í Áö¿ªÀº?

¼Ò¾Æ ºÎ¹®Àº Á¶±â °ËÁø ÇÁ·ÎÅäÄݰú ¼ºÀå±â µ¿¾È ÀϰüµÈ Ä¡·á ¼ö¿ä·Î ÀÎÇØ GHD Ä¡·á ½ÃÀåÀ» Áö¼ÓÀûÀ¸·Î ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¼ºÀÎ GHD Áø´ÜÀº ½ÉÇ÷°ü °Ç°­, Á¤½Å °Ç°­ ¹× ´ë»ç Á¶Àý¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀÌÇØ Áõ°¡·Î ÀÎÇØ ¼ºÀÎ GHD Áø´ÜÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³»ºÐºñ³»°ú Àü¹®ÀǵéÀº ÇöÀç µÎ°³°ñ ¹æ»ç¼± Á¶»ç, ³úÇϼöü ¼ö¼ú, ¿Ü»ó¼º ³ú¼Õ»óÀ» ÀÔÀº ¼ºÀÎÀ» º¸´Ù Àû±ØÀûÀ¸·Î ½ºÅ©¸®´×Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ±âÁ¸ÀÇ Áø´Ü ÇÁ·¹ÀÓ¿öÅ©¿¡¼­ °£°úµÇ¾ú´ø Áý´ÜÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¿©ÀüÈ÷ °¡Àå Å« ½ÃÀåÀ¸·Î, °­·ÂÇÑ ÇコÄɾî ÀÎÇÁ¶ó, È£¸£¸ó ¿ä¹ý¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ º¸Çè Àû¿ë, Ȱ¹ßÇÑ Àӻ󿬱¸°¡ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. À¯·´Àº Àå±âÁö¼ÓÇü Ä¡·áÁ¦ÀÇ Ã¤Åà Áõ°¡¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß»êÃþÀÇ ÀÇ·á Á¢±Ù¼º È®´ë, ¼Ò¾Æ ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áß±¹, Àεµ, Çѱ¹ µîÀÇ ³»ºÐºñ Áø´Ü ´É·Â Çâ»óÀ¸·Î ÀÎÇØ °í¼ºÀå Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À̵é Áö¿ª¿¡¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº Ä¡·á ºñ¿ë Àý°¨°ú ȯÀÚ Á¢±Ù¼º È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù.

¼ºÀåÈ£¸£¸ó °áÇÌÁõ ½ÃÀåÀÇ ¼ºÀåÀº Ä¡·á¹ý Çõ½Å, ÃÖÁ¾ »ç¿ëÀÚ È®´ë, ÀÇ·á ½Ã½ºÅÛ ¹ßÀü¿¡ ±â¹ÝÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å, ƯÈ÷ Áö¼ÓÇü ¼ºÀåÈ£¸£¸ó À¯»çü ¹× ÷´Ü Àü´Þ ÀåÄ¡ÀÇ Ãâ½Ã´Â ¼øÀÀµµ °³¼±, Åõ¾à ºÎ´ã °¨¼Ò, ȯÀÚ ¸¸Á·µµ Çâ»óÀ¸·Î Ä¡·á ÆÐ·¯´ÙÀÓÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ rhGH Á¦Á¦ÀÇ °³¹ßµµ ÇÕ¸®ÀûÀÎ °¡°Ý´ëÀÇ Á¦Ç°À» ´Ã¸®°í ºñ¿ë¿¡ ¹Î°¨ÇÑ Áö¿ªÀ¸·Î ½ÃÀå ħÅõ¸¦ È®´ëÇÔÀ¸·Î½á ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµ Ãø¸é¿¡¼­´Â ¼ºÀÎ Áø´Ü ±â¹Ý È®´ë, Çб³ ¹× Ŭ¸®´ÐÀÇ ¼Ò¾Æ°ú °ËÁø Áõ°¡, ³»ºÐºñ °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡°¡ Àü ¿¬·ÉÃþ¿¡ °ÉÃÄ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ³»ºÐºñ Àü¹® Ŭ¸®´ÐÀÇ È®´ë¿Í µðÁöÅÐ °Ç°­ ¸ð´ÏÅ͸µ µµ±¸ÀÇ ÅëÇÕÀº Àå±âÀûÀÎ Ä¡·áÀÇ ½ÃÀÛ°ú °ü¸®¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ¼±Áø±¹ ½ÃÀå¿¡¼­ÀÇ À¯¸®ÇÑ »óȯ Á¦µµ¿Í Èñ±Í ³»ºÐºñ Áúȯ¿¡ ƯȭµÈ Àü¹® ¹ÙÀÌ¿À Á¦¾à»çÀÇ Á¸Àç°¨ÀÌ ³ô¾ÆÁö¸é¼­ Á¦Ç° Çõ½Å°ú Á¢±Ù¼ºÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªÇÐÀÌ °áÇÕÇÏ¿© ¼ºÀåÈ£¸£¸ó °áÇÌÁõ ½ÃÀåÀº ȯÀÚ Áß½ÉÀÇ ±â¼ú ±â¹Ý Ä¡·á Á¦°øÀÇ »õ·Î¿î ½Ã´ë·Î ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(Ä¡·áÁ¦, ÀçÁ¶ÇÕ Àΰ£ ¼ºÀå È£¸£¸ó, Àΰ£ ³úÇϼöü ÃßÃâ¹°, ¼ö¼ú); Áúº´ ÀûÀÀÁõ(¼Ò¾Æ ¼ºÀå È£¸£¸ó °áÇÌÁõ, Ư¹ß¼º Àú½ÅÀåÁõ, SGA(Small for Gestational Age), ÅÍ³Ê ÁõÈıº, ¼ºÀÎ ¼ºÀå È£¸£¸ó °áÇÌÁõ, ±âŸ Áúº´ ÀûÀÀÁõ); Åõ¿© °æ·Î(ÇÇÇÏ Åõ¿© °æ·Î, ±ÙÀ° ³» Åõ¿© °æ·Î, Á¤¸Æ Åõ¿© °æ·Î); À¯Åë ä³Î(º´¿ø ¾à±¹ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î).

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 34°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

¹«·á ¾÷µ¥ÀÌÆ® °¢±¹ÀÇ ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ, 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» °í°´´Ôµé²² Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Growth Hormone Deficiency Market to Reach US$5.2 Billion by 2030

The global market for Growth Hormone Deficiency estimated at US$4.4 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Therapeutic Treatment, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Recombinant Human Growth Hormone Treatment segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 5.7% CAGR

The Growth Hormone Deficiency market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Growth Hormone Deficiency Market - Key Trends & Drivers Summarized

Why Is Growth Hormone Deficiency Becoming a More Prominent Concern in Pediatric and Adult Health?

Growth Hormone Deficiency (GHD), a rare but significant endocrine disorder, is receiving increased global attention due to rising diagnostic awareness and expanding therapeutic interventions across pediatric and adult populations. GHD occurs when the pituitary gland fails to produce sufficient levels of growth hormone, leading to delayed growth in children and metabolic imbalances in adults. While traditionally viewed as a pediatric condition, adult-onset GHD-linked to pituitary tumors, trauma, or aging-is now being more frequently diagnosed, contributing to broader patient demographics and sustained treatment demand.

Globally, the incidence of GHD remains relatively low, but the condition’s complex presentation and long-term complications have driven clinical focus on early detection and intervention. In children, untreated GHD leads to short stature, delayed puberty, and poor bone development. Among adults, symptoms include reduced muscle mass, fatigue, increased fat accumulation, and diminished quality of life. These manifestations, coupled with advancements in hormone level screening and imaging diagnostics, have led to improved identification rates across geographies. Increased healthcare access and awareness campaigns by endocrine associations are further expanding the diagnostic footprint, particularly in emerging markets.

How Are Treatment Modalities Evolving in Response to Patient Needs and Innovation?

The standard treatment for GHD involves daily subcutaneous injections of recombinant human growth hormone (rhGH), a therapy that has proven to be effective in restoring hormone levels and improving clinical outcomes. However, the burden of frequent injections and adherence challenges-especially among children-have led to significant innovation in drug formulation and delivery methods. Long-acting growth hormone analogs, such as somapacitan and lonapegsomatropin, are now entering the market, offering weekly or even less frequent dosing options, thereby improving patient convenience and compliance.

Biopharmaceutical companies are also investing in needle-free delivery technologies, sustained-release microsphere systems, and autoinjector pens that simplify administration and reduce injection-associated discomfort. In parallel, personalized treatment approaches leveraging biomarkers and genetic profiling are being explored to tailor dosing strategies and monitor therapeutic response with greater precision. Digital health platforms that enable remote monitoring, patient reminders, and mobile-based adherence tracking are increasingly being integrated with GHD management protocols, especially in developed regions where telehealth infrastructure is mature.

Which Segments and Regions Are Emerging as Growth Catalysts in This Market?

The pediatric segment continues to dominate the GHD treatment market due to early screening protocols and consistent therapy demand throughout a child’s developmental years. However, adult GHD diagnosis is gaining traction, fueled by increased understanding of its impact on cardiovascular health, mental well-being, and metabolic regulation. Endocrinologists are now more proactive in screening adults who have undergone cranial irradiation, pituitary surgeries, or experienced traumatic brain injuries-populations previously overlooked in traditional diagnostic frameworks.

From a regional perspective, North America remains the largest market, supported by strong healthcare infrastructure, broad insurance coverage for hormonal therapies, and active clinical research. Europe follows closely, with increasing adoption of long-acting therapies and favorable reimbursement policies. Asia-Pacific is emerging as a high-growth region due to expanding middle-class healthcare access, rising pediatric care awareness, and improved endocrine diagnostic capabilities in countries such as China, India, and South Korea. Additionally, regulatory approvals of biosimilars in these regions are helping to lower treatment costs and expand patient access.

The Growth in the Growth Hormone Deficiency Market Is Driven by Several Factors…

The growth in the growth hormone deficiency market is driven by several factors rooted in therapeutic innovation, end-user expansion, and healthcare system advancements. Technological innovations-particularly the launch of long-acting growth hormone analogs and advanced delivery devices-are reshaping treatment paradigms by improving adherence, reducing administration burden, and enhancing patient satisfaction. The development of biosimilar rhGH products is also contributing to market growth by increasing affordability and broadening market penetration in cost-sensitive regions.

On the end-use front, the widening diagnostic base among adults, increased pediatric screening in schools and clinics, and rising awareness about endocrine health are driving sustained demand across age groups. The expansion of specialty endocrinology clinics, coupled with the integration of digital health monitoring tools, is making it easier to initiate and manage long-term therapy. Furthermore, favorable reimbursement structures, particularly in developed markets, and the increasing presence of specialty biopharma players focused on rare endocrine disorders are accelerating product innovation and access. Collectively, these dynamics are propelling the growth hormone deficiency market into a new era of patient-centric, technology-enabled treatment delivery.

SCOPE OF STUDY:

The report analyzes the Growth Hormone Deficiency market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery); Disease Indication (Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, Other Disease Indications); Administration Route (Subcutaneous Administration Route, Intramuscular Administration Route, Intravenous Administration Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â